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Ocular involvement of chronic graft-versus-host disease (cGVHD) is a complication that occurs in up to 60% of
patients after allogeneic hematopoietic stem cell transplantation. Conventional therapeutic options include
medical and surgical procedures that are administered depending on the severity of the condition, but most
of them have provided unsatisfactory results and, to date, there is no consensus about treatment. We
considered that topical application of a platelet lysate, administered as eye drops, might be considered an
alternative worthwhile of investigation to treat ocular surface disorders in patients suffering from cGVHD.
Therefore, we conducted a single-center prospective pilot study to assess the efficacy and safety of using eye
drops made from reconstituted lysed platelet concentrate. Twenty-six patients with ocular cGVHD were
eligible for the study; all but 2 completed their scheduled 1-year treatment and complied with the hema-
tologic and ophthalmic regimen. At their first assessment interviews, after 30 days of treatment, 91% of
patients reported an improvement in their symptoms and for 32%, substantive objective differences were
measured. Remission of corneal damage was seen for 86% of our cohort, and improved National Institutes of
Health scores for 73%, of whom 8% achieved the best score of 0 (ie, nonedry eye). Similar results were seen at
later time points. Comparing outcomes for our patient cohort to those determined retrospectively for patients
in our institutional database revealed a 5-year overall survival (OS) of 65%. This OS is comparable to patients
with limited cGVHD (75%) and is superior to that of patients with nonocular extensive cGVHD or without
cGVHD (30% and 59%, respectively) (P ¼ .013). Our results suggest that platelet-derived eye drops are a safe,
practical, and well-tolerated therapeutic option that offers substantial benefits for most patients affected by
ocular cGVHD at onset. The favorable OS of our patient cohort suggests that this topical therapy, rather than
systemic immunosuppression, may be the treatment of choice.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic (allo) hematopoietic stem cell transplantation
(HSCT) is a potentially curative approach for several hema-
tologic neoplasms [1]. According to most registries, theedgments on page 1670.
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ty for Blood and Marrow Transplantation.number of patients is growing mostly because of an increase
of transplantations from unrelated and haplo-identical do-
nors. Less aggressive conditioning regimens and improved
supportive care have led to a reduction in treatment-related
mortality, with patients ages 60 to 65 years routinely able to
undergo this procedure [2].
Despite significant advances in the allo-HSCT field, graft-
versus-host disease (GVHD) remains the most important
cause of morbidity and mortality after transplantation.
Although acute GVHD (aGVHD) has a considerable impact on
nonrelapse mortality (NRM), chronic GVHD (cGVHD) is the
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70% of adults who survive for more than 100 days after
receiving their transplantation [3]. cGVHD has been associ-
ated with a reduced risk of relapse, possibly because of a
concomitant graft-versus-leukemia effect [4-6]. Despite this,
cGVHD correlates with increased morbidity and mortality
and has a major impact on the quality of life of subjects who
have undergone allo-HSCT [7].
Ocular complications develop in a substantial percentage
of patients after allo-HSCT as part of aGVHD or cGVHD.
Ocular manifestations of aGVHD, ranging from conjunctival
hyperemia to pseudomembraneous conjunctivitis, are un-
common but reported in literature because they might be
associated with irreversible ocular damage and very poor
prognosis [8]; ocular complications are more frequently
associated with the occurrence of systemic cGVHD and arise
in up to 60% of such cases [9,10]. This pathology results from
the infiltration of the lacrimal gland by fibroblasts and T
lymphocytes; these infiltrates provoke impaired secretory
function and corneal damage [11,12]. Common symptoms of
ocular cGVHD include inflammation and ocular discomfort,
such as photophobia, pain, foreign body sensation, and dry
eyes (xerophthalmia). Infectious conjunctivitis is also a
frequent complication. Treatment usually involves steroids
and artificial tears, neither of which are satisfactory. Ordi-
narily, the patient will continue to experience considerable
discomfort and suffer reduced visual acuity and poorer
quality of life [13].
Based on these unsatisfactory responses, there is
considerable interest in developing alternative treatments
with which to control autoimmunity, suppress inflamma-
tion, and promote tissue regeneration. We reasoned that an
attractive strategy that could reverse the underlying patho-
logical processes of cGVHD could be the topical application of
an autologous platelet concentrate, lysed, and then recon-
stituted as eyes drops (PClys) [14-16]. The rationale for this
approach is the capacity of blood components to enhance
healing and stimulate tissue regeneration. In particular,
platelet concentrates have a demonstrable positive impact
on wound healing by modulating its different phases, espe-
cially re-epithelialization and tissue remodeling [17]. The
bioactive components are likely vitamins, growth factors
(GF), and fibronectin, all of which are required for corneal
and conjunctival integrity; modulators of the inflammatory
response are possibly also involved [18,19].
In ophthalmology, eye drops comprising platelet-rich
plasma have been successfully used to treat dry eye syn-
drome for patients with Sjogren’s disease [20]; the adoption
of this approach for patients with ocular cGVHD has been
suggested [21]. A caveat to this approach is that reports of
platelet-rich plasma’s success were retrospective and
involved small numbers of patients [22]. We therefore
designed a phase II clinical study to offer PClys eye drops to
patients who had undergone allogeneic transplantation and
were diagnosed with ocular cGVHD. We now report the re-
sults of this trial with a focus on the following: (1) the
characteristics of patients with ocular cGVHD in terms of
general clinical outcome and (2) feasibility and efficacy of
PClys eye drops for the treatment of ocular cGVHD.
METHODS
Patients
This study was conducted at the SS Antonio e Biagio e Cesare Arrigo
Hospital, Alessandria, by a consortium of the hematology, ophthalmology,
and transfusion divisions. Since 2005, follow-up had been provided by local
ambulatory services for patients who survived for more than 100 days afterallo-HSCT. Follow-up involved systematic cGVHD screening, based on the
Seattle [23] and National Institutes of Health (NIH) criteria [24] (the latter
assigned retrospectively). A subjective activities of daily living scorewas also
collated. All patients receiving allo-HSCT for a hematologicmalignancy were
requested to complete a self-administered, subjective, questionnaire about
their ocular disability (the Ocular Surface Disease Index) [25]. This was used
to identify patients with suspected ocular cGVHD. Patients scoring greater
than 15 were referred to an ophthalmologist for a formal diagnosis and
assessment for study eligibility.
Treatment with the PClys eye drops was offered from January 2007 to
January 2014. Eligibility criteria for enrollment were (1) recent diagnosis of
ocular cGVHD, (2) no active systemic or ophthalmic disease other than
cGVHD, (3) absence of major systemic comorbidity other than those related
to systemic cGVHD, (4) adequate control of primary hematological
neoplasmwith life expectancy> 3months, and (5) a platelet count in excess
of 100 103/mL. After their enrollment in the study, all patients underwent a
scheduled ophthalmic evaluation at days þ30, þ180, and þ360. Additional
evaluations where conducted on an ad hoc basic. Ophthalmic analyses
included both subjective and objective tests. Subjective symptoms as pain,
photophobia, and eye dryness were assessed according to the NIH Eye Score
and Ocular Surface Disease Index questionnaire. Objective tests included
Schirmer’s test to assess the ability of the eye to produce sufficient lachrymal
fluid to stay moist; a tear film break-up time test; and a best visual acuity
score. In Schirmer’s test, the ability to moisten a 15-mm paper strip was
considered our reference (normal) value and a 5-mm increase was rated as
improved; for the tear film break-up time test, > 10 seconds was the
reference time and a 5-second increase was considered improved. Finally,
there was an assessment of corneal damage, which comprised fluorescein
score and lissamine score. The study was planned to be of exploratory na-
ture without definition of a formal hypothesis of efficacy. Enrollment was
allowed for 7 years with the aim of enrolling at least 28 patients with ocular
cGVHD. All patients gavewritten consent before inclusion in the study; their
treatment was authorized by our local ethical committee (Prot. n ASO.-
Tras07.04 del CE 18/04/2007).
Preparation and Administration of the CP Lysate Eye Drops
The preparation of PClys eye drops has been described previously [26].
Briefly, 60 mL of anticoagulated peripheral blood was collected from each
patient and centrifuged to obtain an autologous platelet concentrate. The
concentrate (at .7  106/mL) was frozen and thawed (80C/37C) to lyse
platelets. The lysate was then diluted with sterile balanced saline solution
(30% V/V) and aliquoted as 30 ready-to-use, sterile doses (Col System, Bio-
med DeviceModena, Italy). The eye dropswere stored frozen (20C) by the
study participants, who used them daily. All samples were subject to
microbiological control to verify sterility. Patients were provided with a
monthly supply of eye drops. Patient training was provided for storage (the
sterile vials were frozen in home freezers for up to 30 days), the thawing
protocol (vials were thawed and then stored for the day at 4C), and topical
application (2 eye drops per eye, 6 times each day for the duration of the
1-year treatment period).
Statistical Analyses
Data were collected in a computerized database and analyzed using the
SPSS version 18.0 statistical package. Response criteria for ocular cGVHD
were measured based on improvement, stability, or worsening NIH score.
Subjective and objective tests were analyzed using Wilcoxon signed-rank
test.
Overall survival (OS) was defined as the probability of survival regardless
of disease state; its distributions over time were estimated by the Kaplan-
Meier product limit method with log-rank tests to assess differences be-
tween groups. It was calculated with 2 different time points. OS was
calculated for all patients starting from day þ100 after allo-HSCT to censor
early death after allo-HSCT. OS was also calculated for patients with ocular
GVHD from the date of onset of ocular symptoms and for the other patients
from day þ100 after allo-HSCT, after the analysis by Jacobs et al. [27]
(Figure 1S).
NRM was defined as the probability of dying without previous occur-
rence of a relapse, which is a competing event. The cumulative incidence
function for NRMwas estimated by the Gray test (comparing the cumulative
incidence curve of the main event [death without relapse] in the presence of
the competing event [relapse]). All reported P values were obtained by the
2-sided exact method, at the conventional 5% significance level.
RESULTS
Patient Characteristics and Outcome
From March 2005 until August 2014, a total of 127 pa-
tients underwent allo-HSCT transplantation at our
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up was 654 days (range, 10 to 3486). The treated neoplasms
included 53 (42%) acute myeloid leukemias, 10 (8%)
myelodysplastic syndrome, 16 (13%) acute lymphoblastic
leukemias, 24 (19%) non-Hodgkin lymphoma or chronic
lymphocytic leukemias, 7 (5%) multiple myelomas, 5 (4%)
Hodgkin lymphomas, and 12 (9%) other hematological ma-
lignancies. GVHD prophylaxis consisted of an inhibitor of
calcineurin (cyclosporine or tacrolimus) combined with
methotrexate or mycophenolate mofetil. Patient and disease
characteristics, type of conditioning regimen, source of stem
cells, and information about occurrence of GVHD and NRM
events are illustrated in details in Table 1.
Occurrence of Ocular cGVHD
Twenty-nine patients (23% of the allo-HSCT population)
developed ocular cGVHD; these patients were treated for
acute myeloid leukemia (10 patients, 34% of the cohort),
myelodysplastic syndrome (6 patients, 20%), acute lympho-
blastic leukemia (3 patients, 7%), and non-Hodgkin lym-
phoma (3 patients, 10%). Seven patients (24%) were treatedTable 1
Patient Characteristics
Characteristic Value
Gender
Male 69 (54%)
Female 58 (46%)
Diagnosis
AML 53 (42%)
NHL 18 (14%)
ALL 16 (13%)
MDS 10 (8%)
Other 30 (23%)
Conditioning regimen
Myeloablative 77 (61%)
Reduced intensity 50 (39%)
Source of stem cells
PB 111 (87%)
BM 16 (13%)
Type of donor
Sibling donors 56 (44%)
MUD 68 (53%)
Haploidentical 4 (3%)
T cell depletion
ATG 64 (50%)
Campath 1 (<1%)
GVHD
Acute 19 (15%)
Chronic 72 (57%)
Extent of cGVHD
Limited 13 (10%)
Extensive 59 (47%)
Ocular GVHD
No 98 (77%)
Yes 29 (23%)
Relapse after HSCT
No 93 (73%)
Yes 34 (27%)
Death
No 78 (61%)
Yes 49 (39%)
Cause of death (before day 100)
Progression of disease 9
Viral encephalitis (suspected) 1
aGVHD 1
Refractory hemolytic anemia 1
Multiorgan failure 1
AML indicates acute myeloid leukemia; NHL, non-Hodgkin lymphoma; ALL,
acute lymphoblastic leukemia; MDS, myelodysplastic syndrome;
PB, peripheral blood; BM, bone marrow; MUD, matched unrelated donor;
ATG, antithymocyte globulin.for other hematological malignancies. Seventeen patients
(58%) received a myeloablative conditioning and 12 received
(42%) a reduced-intensity conditioning. The median follow-
up was 1087 days after allo-HSCT, with a range of 241 to
2947 days. Median time of onset of ocular GVHD was
218 days (range, 90 to 1750 days). Clinical characteristics of
the 29 patients who developed ocular cGVHD are illustrated
in Table 2; a detailed description of ocular manifestations at
baseline is reported in Table 3.Treatment with PClys Eye Drops
Patient flow through our clinical study is shown in
Figure 1. Of 29 patients diagnosed with ocular cGVHD, 26
were eligible for our study; 3 patients could not be enrolled
for the following reasons: 1 patient with multiple myeloma
was excluded because of rapidly progressing disease; 1 pa-
tients acute lymphoblastic leukemia patient was excluded
because of severe, systemic concurrent symptoms; for the
third patient, use of an antibiotic eyewash rapidly improved
his ocular symptoms to a statewhere inclusionwas no longer
appropriate. Five of 26 patients (19%) were classified as NIH
score 1, 18 patients (69%) scored 2, and 3 patients (12%)
scored 3.
The median age of the cohort of 26 patients enrollment in
the study was 60 (range, 24 to 67) and their median time
from transplantation to enrollment was 258 days (range, 97
to 1750). Ocular cGVHD arose in 24 of 26 patients experi-
encing contemporary involvement of other organs; these
patients restarted or increased immunosuppressive medi-
cations with the addition of PClys eye drops; 2 of 26 patients
developed only ocular cGVHD and PClys eye drops were used
as a stand-alone treatment. For 9 patients, ocular cGVHDwas
the sole manifestation defining extensive cGVHD.
All but 2 of our patients starting treatment completed
their 1-year treatment schedule; 1 patient stopped his
participation in the first few days because of treatment-
associated ocular pain, burning, and conjunctival hyper-
emia; the episode resolved in few days with discontinuation
of the eye drops. No evidence for infectionwas ever detected.
Poor compliance was seen for the second patient, despite
encouraging initial results. Among patients who underwent
the planned treatment, the following results were observed:
at day þ30, 91% had an improvement of symptoms, 32%
showed an improvement of objective criteria, and 86%
demonstrated a remission of corneal damage. From a he-
matological point of view, 73% had an improved NIH score,
with 8% attaining a 0 score. Positive results were also
confirmed at þ180 days: 86% reported continued subjective
benefits, 59% experienced improved objective function, and
86% had remission of corneal damage. A further 8% improved
their NIH score: 27% were now graded 0. These findings were
confirmed at day þ360. Results detailing these ophthalmo-
logical improvements are summarized in Figure 2 and a
complete analysis of subjective and objective tests’ results
are shown in Table 3. None of the cohort had to further
increase their systemic immunosuppressive therapy. It is
worthwhile to note that during their eye drop therapy, 5 of
the 9 patients manifesting ocular-only symptoms of exten-
sive cGVHD (55%) were able to progressively taper and ulti-
mately cease their systemic immunosuppressive therapies.
After 1 year of treatment, only 1 patient continued to use
the eye drops because of persistent kerato-conjunctivitis.
Results of treatment with PClys eye drops are detailed in
Table 3.
Table 2
Clinical Characteristics at Enrollment
Patient Disease Gender Age, yr Source of
Stem Cells
Type of
Donor
cGVHD Other
than Eyes
Ocular
NIH Score
Global Scoring
of GVHD
Ocular GVHD
as the Sole
Manifestation of
Extensive cGvHD
Days from HSCT to
Ocular GVHD
1 AML M 55 PB Related Skin, mouth 2 Severe No 1750
2 RAEB-2 F 53 PB Related Skin 2 Moderate Yes 1738
3 AML M 60 PB Related No 3 Moderate Yes 324
4 NHL M 51 PB Related Mouth, liver 1 Moderate No 202
5 AML M 23 PB Related Mouth 2 Mild No 195
6 AML M 36 BM MUD Skin, mouth 2 Moderate No 1071
7 AML M 46 PB Related Mouth 3 Moderate No 210
8 RAEB-1 M 64 PB Related Skin 2 Mild Yes 376
9 NHL F 33 PB Related Skin, mouth, joint 3 Severe No 206
10 CML M 59 PB Related Skin, mouth, joint 2 Severe No 502
11 MI M 51 PB MUD Skin, joint 2 Severe No 280
12 CLL F 66 PB MUD No 1 Mild Yes 294
13 RAEB-1 M 66 PB Related Skin 2 Moderate Yes 406
14 MM M 65 PB MUD Skin 1 Mild Excluded 203
15 AML M 52 PB Related Lung, mouth 2 Severe No 426
16 AML M 63 PB MUD Skin 1 Mild Yes 193
17 AML F 50 PB Related Liver, mouth 2 Moderate No 218
18 MM M 60 PB MUD Gut, skin 2 Severe Excluded 141
19 BPDCN M 64 PB MUD Mouth 2 Moderate No 280
20 MM F 62 PB MUD Mouth 2 Mild No 275
21 ALL F 64 PB MUD Skin 2 Mild Yes 141
22 AML F 63 BM MUD Mouth 2 Moderate No 211
23 ALL M 25 PB Related Skin, mouth 2 Moderate No 362
24 MDS M 63 BM MUD Mouth 1 Mild No 241
25 AML F 61 PB MUD Skin 2 Mild Yes 98
26 MDS M 64 PB Related Sierositis 2 Moderate No 146
27 MDS M 47 PB Related Mouth, skin 2 Moderate No 181
28 NHL F 53 PB MUD No 1 Mild Yes 97
29 ALL F 37 PB Related Skin, lung 3 Severe Excluded 90
M indicates male; RAEB, refractory anemia with excess blasts; F, female; CML, chronic myeloid leukemia; MI, myelofibrosis idiopathic; CLL, chronic lymphocytic
leukemia; MM, multiple myeloma; BPDCN, blastic plasmacytoid dendritic cell neoplasm.
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Extraocular GVHD
Of the 26 patients diagnosed with ocular cGVHD, 6 (20%)
relapsed after allo-HSCT and 4 (15%) died of disease pro-
gression. Twenty-two patients (76%) are currently alive at
follow up.
To understand the outcome of our cohort of patients, we
compared OS and NRM curves based on the presence of
ocular involvement (29 patients) versus patients with
extraocular cGVHD (limited, 13 patients and extensive, 30
patients) or without evidence of this complication (55 pa-
tients). In OS analysis, 11 patients were censored because of
early death before day þ100. We found that 5-year OS ofTable 3
Subjective and Objective Results of Patients treated with Platelet-Derived Eye Dro
Baseline 30 Days
Score Score Difference w
Baseline
Symptoms
OSDI score (range) 69 (27-93) 51 (81-15) 18 (3 to
NIH score (range) 2 (1-3) 1 (0-3) 1 (1 to
Test
Schirmer test (mm/5 min) 7 (1-25) 13 (6-26) þ6 (10 to
TBUT test (range), sec 4 (0-8) 7 (3-15) þ3 (þ1 to
BCVA test (range), decimals 9 (4-10) 10 (8-10) þ1 (0 to þ
Damage
Flurescein score 1 (0-3) 0 (0-2) 1 (1 to
Lissamine score 1 (0-3) 0 (0-2) 1 (2 to
OSDI indicates ocular surface disease index; TBUT, tear break-up test; BCVA, best
OSDI score: minimum ¼ 0 maximum ¼ 100; NIH score: minimum ¼ 0 maximu
values > 10 seconds; BCVA: minimum 0/10; maximum 10/10; fluorescein/lissamin
conjuctival damage). Values are expressed as medians.patients with ocular cGVHDwas 65%, which is comparable to
that of patients with limited cGVHD (75%). This was signifi-
cantly better than OS of patients with extensive nonocular
cGVHD or without cGVHD, which were 30% and 59%,
respectively (P ¼ .013) (Figure 3). Interestingly, the 9 patients
who were classified as having extensive cGVHD only for
ocular symptoms had a 3-year OS of 100%. Figure 1S shows
similar results, with slightly lower OS rate for oGVHD at 60%
(P ¼ .024).
Patients with extensive ocular cGVHD had a significantly
better cumulative incidence of NRM (19.6%, 7.7%, 34.7%, and
3.6% at 3 years for patients without cGVHD, with limited
cGVHD, with extensive nonocular cGVHD, and withps
180 Days
ith P Value Score Difference with
Baseline
P Value
þ12) .074 21 (72-12) 48 (72 to þ3) .004
0) .0001 1 (0-2) 1 (2 to 0) .0001
þ22) .091 10 (3-30) þ3 (13 to þ27) .126
þ9) .005 9 (4-15) þ5 (4 to þ11) .011
4) .02 10 (9-10) þ1 (0 to þ6) .034
0) .003 0 (0-1) 1 (2 to 0) .003
0) .004 0 (0-1) 1 (2 to 0) .005
corrected visual acuity.
m ¼ 4; Schirmer test: normal values > 15 mm/5 min; TBUT test: normal
e score: Oxford scheme (0 ¼ absence of conjuctival damage; 5 ¼maximum
Figure 1. CONSORT flow diagram of study protocol.
F. Zallio et al. / Biol Blood Marrow Transplant 22 (2016) 1664e16701668extensive ocular cGVHD, respectively [P ¼ .016]) (Figure 4).
Conversely, no statistically significant difference was
reported for the cumulative incidence of relapse when
stratified by the same risk factor (31.6%, 33.6%, 21.5%, and
22.1%, respectively, P ¼ .406).Figure 2. Ophthalmic improvemDISCUSSION
We now report the results of a prospective pilot study
using platelet-derived eye drops to treat ocular cGVHD. Our
results indicate that PClys eye drops were a safe, feasible, and
well-tolerated therapeutic option. They resulted in aent during study protocol.
Figure 3. Overall survival stratified for cGVHD. Survival is measured from
day 100.
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therapeutic improvement and favorable outcome in those
patient in which ocular cGVHD was the most severe symp-
tom of their extensive cGVHD indicate that these patients in
particular are ideal candidates for this topical treatment.
cGVHD is a common complication of allo-HSCT for pa-
tients surviving more than 100 days. cGVDH has substantial
negative implications for quality of life as a result of impaired
functional status and often leads to the resumption of
immunosuppressive therapy or escalation to more intensive
immunosuppressive therapy. For this reason, cGVHD is the
leading cause of morbidity and NRM. Ocular symptoms
develop in a substantial percentage of patients after allo-
HSCT and often represent 1 of the most invalidating mani-
festation. Indeed, ocular cGVHD often leads to severe ocular
symptoms, resulting in decreased quality of life and restric-
tion of daily activities. Consequently, ocular cGVHD is a cri-
terion used to define “extensive cGVHD” according to the
Seattle scoring system [23].
Little is known about the influence of ocular cGVHD on
survival. For this reason, we split our patients with extensive
cGVHD into 2 groups based on ocular involvement. Our re-
sults suggest that patients with ocular cGVHD show no
increased mortality in comparison to those with limitedFigure 4. Nonrelapse mortality by occurrence of cGVHD.cGVHD. Moreover, those patients with ocular cGVHD as the
sole manifestation of their extensive cGVHD had an OS of
100% at 3 years. Although we have no historical comparison,
we believe that this is clearly not an effect of the local
treatment applied, as this observation was already reported
in previous studies [27,28]. It is possible that the better
general outcome of patients with ocular GVHD is not the
consequence of a different disease biology but rather an
overestimation of the severity of cGVHD in the Seattle clas-
sification system compared to the more recent NIH
consensus criteria. Indeed, these novel criteria do not
consider ocular cGVHD as a parameter of more severe
cGVHD. This suggests that the isolated ocular disease, while
severe in terms of quality of life and local complications, does
not have a major impact on the global burden of cGVHD-
related autoimmune phenomena. Consequently, these data
indicate that ocular cGVHD is an excellent candidate for
topical rather than for systemic treatment. To date, only 2
studies have compared outcomes for ocular versus cGVHD. In
agreement with our findings, Jacobs et al. recently described
a superior 2-year survival among patients with ocular GVHD
versus extraocular [27]. Furthermore, Inamoto et al., in a
multicenter observational study, reported that an NIH eye
score of 2 or 3 was associated with a decreased risk of
recurrent malignancy [28].
The treatment of ocular cGVHD is still not standardized;
instead, recommended treatments are based on retrospec-
tive series and a few small prospective studies. Previous
studies of ocular cGVHD have addressed the efficacy of reti-
noic acid [29], topical calcineurin inhibitors such as cyclo-
sporine .05% and tacrolimus eye drops [30], and systemic
treatments. Tacrolimus .03% eye drops are most commonly
prescribed. These are more popular than cyclosporine eye
drops because of their good tolerability and direct local
immunosuppressive effect [31]. That said, the study that
came to this conclusion had a sample size that was too small
to be able to draw any definitive statement about safety and
efficacy.
The benefits of autologous serum (AS) eye drops for the
treatment of dry eye syndrome related to cGVHD was re-
ported by Rocha et al. [32]. It was assumed that serum could
recapitulate the function of lacrimal fluid. Indeed, AS eye
drops are a rich source of GF, in particular epithelial GF,
which induces proliferation and limits apoptosis; serum
proteins (fibronectin and vitamin A); and cytokines that
improve the healing of the corneal epithelium and con-
junctiva [33].
PClys eye drops can provide additional advantages
compared with AS eye drops. In particular, their increased
concentration of platelet GF (platelet-derived GF, fibronectin,
epidermal growth factor, and transforming GF b) can stim-
ulate a faster ocular re-epithelialization [34]. Indeed PClys
eye drops might exert a more extensive action; the plasma
component contains proteins essential for surface lubrica-
tion, whereas platelets donate GFs with which to induce the
tissue regeneration needed to accelerate healing.
Based on this rationale, we decided to treat patients with
ocular cGVHD using a preparation of PClys eye drops in a
prospective pilot study. The eye drop formulation was stan-
dardized for platelet number [26] and prepared using a
controlled (ie, sterile) and certified procedure. Feasibility of
use and tolerability were excellent. Only 1 patient experi-
enced a local reaction to their eye drops of sufficient
magnitude to interrupt treatment. Notably, we observed no
ocular infections. Our results confirm the efficacy of the
F. Zallio et al. / Biol Blood Marrow Transplant 22 (2016) 1664e16701670experimental treatment, with an improvement of all ocular
cGVHD-related symptoms in almost 80% of patients. Most
notably, improvement was rapid and persistent, resulting in
a considerable improvement in quality of life. At follow-up,
only 1 persistent case of ocular cGVHD was seen, suggest-
ing the long-term benefit of using the PClys eye drops. Based
on the excellent toxicity profile and rapid response achieved,
we are now investigating whether a shortened program
might also allow similar results, without increased risk of
late relapse. As an alternative, one might consider the
development of response-adapted therapeutic regimens, in
which treatment is only indicated when symptoms or signs
of cGVHD reappear. Combination therapy with tacrolimus
ointment, currently being used as a maintenance-treatment
for ocular cGVHD, could also be considered [35].
Our study has some limitations; most notably, the small
sample size, a lack of multicenter validation, and the absence
of a control arm. The possibility of conducting a multicenter
randomized study is currently being investigated and a
number of trials from other institutions are currently
ongoing (https://clinicaltrials.gov/).
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